BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24139550)

  • 1. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
    Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
    BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
    Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
    Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
    Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
    PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
    Pelttari LM; Kiiski JI; Ranta S; Vilske S; Blomqvist C; Aittomäki K; Nevanlinna H
    Springerplus; 2015; 4():92. PubMed ID: 25918678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
    Song H; Dicks E; Ramus SJ; Tyrer JP; Intermaggio MP; Hayward J; Edlund CK; Conti D; Harrington P; Fraser L; Philpott S; Anderson C; Rosenthal A; Gentry-Maharaj A; Bowtell DD; Alsop K; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Høgdall E; Høgdall CK; Jensen A; Kjaer SK; Lubiński J; Huzarski T; Jakubowska A; Gronwald J; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Odunsi K; Goode EL; Menon U; Jacobs IJ; Gayther SA; Pharoah PD
    J Clin Oncol; 2015 Sep; 33(26):2901-7. PubMed ID: 26261251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain).
    Sánchez-Bermúdez AI; Sarabia-Meseguer MD; García-Aliaga Á; Marín-Vera M; Macías-Cerrolaza JA; Henaréjos PS; Guardiola-Castillo V; Peña FA; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2018 Jun; 61(6):355-361. PubMed ID: 29409816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous recombination-deficient mutation cluster in tumor suppressor
    Prakash R; Rawal Y; Sullivan MR; Grundy MK; Bret H; Mihalevic MJ; Rein HL; Baird JM; Darrah K; Zhang F; Wang R; Traina TA; Radke MR; Kaufmann SH; Swisher EM; Guérois R; Modesti M; Sung P; Jasin M; Bernstein KA
    Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2202727119. PubMed ID: 36099300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
    Le Calvez-Kelm F; Oliver J; Damiola F; Forey N; Robinot N; Durand G; Voegele C; Vallée MP; Byrnes G; Registry BC; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV; Lesueur F
    PLoS One; 2012; 7(12):e52374. PubMed ID: 23300655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
    Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
    JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
    Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
    Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor.
    Greenhough LA; Liang CC; Belan O; Kunzelmann S; Maslen S; Rodrigo-Brenni MC; Anand R; Skehel M; Boulton SJ; West SC
    Nature; 2023 Jul; 619(7970):650-657. PubMed ID: 37344587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
    Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
    Johnson J; Healey S; Khanna KK; ; Chenevix-Trench G
    Breast Cancer Res Treat; 2011 Aug; 129(1):255-63. PubMed ID: 21533530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells.
    Liu N; Schild D; Thelen MP; Thompson LH
    Nucleic Acids Res; 2002 Feb; 30(4):1009-15. PubMed ID: 11842113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
    PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
    De Leeneer K; Van Bockstal M; De Brouwer S; Swietek N; Schietecatte P; Sabbaghian N; Van den Ende J; Willocx S; Storm K; Blaumeiser B; Van Asperen CJ; Wijnen JT; Leunen K; Legius E; Michils G; Matthijs G; Blok MJ; Gomez-Garcia E; De Paepe A; Tischkowitz M; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 May; 133(1):393-8. PubMed ID: 22370629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination.
    Setton J; Selenica P; Mukherjee S; Shah R; Pecorari I; McMillan B; Pei IX; Kemel Y; Ceyhan-Birsoy O; Sheehan M; Tkachuk K; Brown DN; Zhang L; Cadoo K; Powell S; Weigelt B; Robson M; Riaz N; Offit K; Reis-Filho JS; Mandelker D
    NPJ Breast Cancer; 2021 Oct; 7(1):135. PubMed ID: 34635660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.